Acetylation turns leucine into a drug by membrane transporter switching.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 08 2021
Historique:
received: 12 05 2021
accepted: 23 07 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 9 11 2021
Statut: epublish

Résumé

Small changes to molecules can have profound effects on their pharmacological activity as exemplified by the addition of the two-carbon acetyl group to make drugs more effective by enhancing their pharmacokinetic or pharmacodynamic properties. N-acetyl-D,L-leucine is approved in France for vertigo and its L-enantiomer is being developed as a drug for rare and common neurological disorders. However, the precise mechanistic details of how acetylation converts leucine into a drug are unknown. Here we show that acetylation of leucine switches its uptake into cells from the L-type amino acid transporter (LAT1) used by leucine to organic anion transporters (OAT1 and OAT3) and the monocarboxylate transporter type 1 (MCT1). Both the kinetics of MCT1 (lower affinity compared to LAT1) and the ubiquitous tissue expression of MCT1 make it well suited for uptake and distribution of N-acetyl-L-leucine. MCT1-mediated uptake of a N-acetyl-L-leucine as a prodrug of leucine bypasses LAT1, the rate-limiting step in activation of leucine-mediated signalling and metabolic process inside cells such as mTOR. Converting an amino acid into an anion through acetylation reveals a way for the rational design of drugs to target anion transporters.

Identifiants

pubmed: 34349180
doi: 10.1038/s41598-021-95255-5
pii: 10.1038/s41598-021-95255-5
pmc: PMC8338929
doi:

Substances chimiques

Large Neutral Amino Acid-Transporter 1 0
Monocarboxylic Acid Transporters 0
Organic Anion Transport Protein 1 0
Organic Anion Transporters, Sodium-Independent 0
Prodrugs 0
SLC22A6 protein, human 0
Symporters 0
monocarboxylate transport protein 1 0
organic anion transport protein 3 0
Leucine GMW67QNF9C
acetylleucine K76S41V71X

Banques de données

ClinicalTrials.gov
['NCT03759639', 'NCT03759665', 'NCT03759678']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15812

Subventions

Organisme : Wellcome Trust
ID : 202834/Z/16/Z
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Physiol Rev. 2015 Jan;95(1):83-123
pubmed: 25540139
Front Chem. 2014 Aug 11;2:61
pubmed: 25157349
Pharm Acta Helv. 1996 Nov;71(5):309-27
pubmed: 8973162
Curr Neuropharmacol. 2019;17(1):7-13
pubmed: 30182858
Orphanet J Rare Dis. 2018 Aug 16;13(1):143
pubmed: 30115089
J Pharm Pharmacol. 2008 May;60(5):543-85
pubmed: 18416933
Eur J Pharm Sci. 2008 Oct 2;35(3):161-74
pubmed: 18656534
Neurology. 2015 Oct 20;85(16):1368-75
pubmed: 26400580
Adv Nutr. 2016 Jul 15;7(4):798S-805S
pubmed: 27422517
Bioorg Med Chem Lett. 2009 May 15;19(10):2844-51
pubmed: 19361989
Brain Commun. 2020 Dec 20;3(1):fcaa148
pubmed: 33738443
J Pharm Sci. 1998 Dec;87(12):1604-7
pubmed: 10189274
Curr Neurol Neurosci Rep. 2016 Apr;16(4):31
pubmed: 26898683
Adv Pharmacol. 2012;63:1-42
pubmed: 22776638
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Toxicol Lett. 2012 Sep 3;213(2):292-8
pubmed: 22828011
Eur J Pharmacol. 2015 Dec 15;769:342-9
pubmed: 26607469
Eur J Neurosci. 2001 Feb;13(4):735-48
pubmed: 11207808
J Pharm Sci. 2003 Aug;92(8):1531-44
pubmed: 12884241
Nat Rev Drug Discov. 2010 Mar;9(3):215-36
pubmed: 20190787
Amino Acids. 2015 May;47(5):917-24
pubmed: 25618754
J Biol Chem. 1947 Aug;169(3):467-76
pubmed: 20259079
Nat Rev Drug Discov. 2010 Aug;9(8):597-614
pubmed: 20671764
Eur J Clin Pharmacol. 2001 Aug;57(5):365-76
pubmed: 11599654
Biochem Pharmacol. 2020 Oct;180:114127
pubmed: 32603666
J Neurosci. 2015 Oct 21;35(42):14353-69
pubmed: 26490872
Eur J Med Chem. 2020 Aug 1;199:112393
pubmed: 32388280
PLoS One. 2020 Feb 27;15(2):e0229585
pubmed: 32108176
J Neurol. 2019 Feb;266(2):525-529
pubmed: 30547273
Eur J Pharm Sci. 2005 Jun;25(2-3):211-20
pubmed: 15911216
J Membr Biol. 1984;77(3):255-64
pubmed: 6699907
Biopharm Drug Dispos. 2010 Jan;31(1):1-71
pubmed: 19953504
Nat Rev Drug Discov. 2011 Mar;10(3):197-208
pubmed: 21358739
J Clin Med. 2020 Apr 08;9(4):
pubmed: 32276303
Asian J Pharm Sci. 2020 Mar;15(2):158-173
pubmed: 32256846
J Neurol. 2013 Oct;260(10):2556-61
pubmed: 23835634
Trials. 2021 Jan 22;22(1):84
pubmed: 33482890
Cell. 2009 Feb 6;136(3):521-34
pubmed: 19203585
Eur J Neurol. 2019 Apr;26(4):694-698
pubmed: 30107068
J Biol Chem. 1946 Jul;164:483
pubmed: 20989507
J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49
pubmed: 11274893
Chemphyschem. 2009 Jul 13;10(9-10):1405-14
pubmed: 19514034
Pediatr Res. 1985 Jun;19(6):514-8
pubmed: 3925425
Eur J Drug Metab Pharmacokinet. 2001 Jan-Jun;26(1-2):71-6
pubmed: 11554437
J Biol Chem. 1998 Sep 11;273(37):23629-32
pubmed: 9726963
Eur J Pharm Sci. 2004 Jan;21(1):53-60
pubmed: 14706811
J Neurochem. 1987 Nov;49(5):1651-8
pubmed: 3668544
FASEB J. 2007 Aug;21(10):2602-12
pubmed: 17395833
Pflugers Arch. 2004 Feb;447(5):666-76
pubmed: 12883891
FEBS J. 2008 Oct;275(19):4740-55
pubmed: 18721135
Metabolism. 2008 Dec;57(12):1747-52
pubmed: 19013300
Amino Acids. 2016 Apr;48(4):1045-1058
pubmed: 26724922
Front Chem. 2018 Jun 22;6:243
pubmed: 29988369
J Pharmacol Exp Ther. 1999 Nov;291(2):705-9
pubmed: 10525090
Biochem Pharmacol. 1966 Oct;15(10):1523-35
pubmed: 5971807
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
Physiology (Bethesda). 2017 Nov;32(6):453-463
pubmed: 29021365
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11178-83
pubmed: 22711801
Am J Clin Nutr. 1985 Oct;42(4):585-96
pubmed: 3931451
IUBMB Life. 2012 Feb;64(2):109-19
pubmed: 22162139
Nat Rev Drug Discov. 2015 Aug;14(8):543-60
pubmed: 26111766
Am J Physiol Renal Physiol. 2004 Aug;287(2):F252-61
pubmed: 15271688
J Drug Target. 1998;6(2):151-65
pubmed: 9886238
J Biol Chem. 1952 Jan;194(1):455-70
pubmed: 14927637
J Neurol. 2016 Jun;263(6):1239-40
pubmed: 27126454
Am J Physiol. 1993 Apr;264(4 Pt 1):C761-82
pubmed: 8476015
Nat Rev Drug Discov. 2007 Nov;6(11):881-90
pubmed: 17971784
Compr Physiol. 2018 Dec 13;9(1):343-373
pubmed: 30549024
Cerebellum Ataxias. 2016 Apr 12;3:8
pubmed: 27073690
Xenobiotica. 2008 Jul;38(7-8):1022-42
pubmed: 18668438
J Biol Chem. 2014 Jun 6;289(23):16278-89
pubmed: 24790103
Science. 2011 Dec 9;334(6061):1408-12
pubmed: 22158820

Auteurs

Grant C Churchill (GC)

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK. grant.churchill@pharm.ox.ac.uk.

Michael Strupp (M)

Department of Neurology and German Center for Vertigo and Balance Disorders, Hospital of the Ludwig Maximilians University, Munich, Germany.

Cailley Factor (C)

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK.

Tatiana Bremova-Ertl (T)

Department of Neurology, University Hospital Inselspital, Bern, BE, Switzerland.
Center for Rare Diseases, University Hospital Inselspital Bern, Bern, BE, Switzerland.

Mallory Factor (M)

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK.

Marc C Patterson (MC)

Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Frances M Platt (FM)

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK.

Antony Galione (A)

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH